Research & Development

Smilax recognizes the fact that Research & Development is a vital component for sustainable, growth and long-term competitive advantage. Smilax has a pool of more than 60 scientists to transform it into a research-driven pharmaceutical company. The focus areas are complex APIs and API Intermediates for both regulated and semi-regulated markets

Research &Development – Core strengths:

Design and synthesis of APIs and their intermediates

Development of non – infringing processes

Identification, isolation/synthesis of impurities

Development of alternative and cost-effective processes

Chiral separations

Studies on polymorphic forms

Intellectual Property Management

In order to emerge as a major player in regulated markets such as the United States and the European Union as well as to evaluate IP issues, Smilax has set up an Intellectual Property Management Group. The Company’s competitive advantage is in capturing a large portfolio of approvals, backed by R&D effort that offers several patented non-infringing processes and intellectual properties, and a cost- effective mega manufacturing environment complying with the regulatory authorities. The process of creating intellectual wealth starts off with judicious product identification, based on technological complexity and emerging opportunities

Intellectual Property Management deals with:

Patent assessment

Interpreting patent claims and handling infringement issues

Handling IP related queries

Finalization of the non-infringing synthetic routes for APIs

Protecting the company’s inventions across the globe

As part of internal IP management, Smilax has signs a Confidentiality Disclosure Agreement (CDA) to protect all sensitive information before commencing business with its prospective business associates.